GFAP and Stroke: While the majority of studies which found significant reductions in IBA+ and GFAP+ cells in the acute and chronic stroke environment administered the therapeutic at subacute time points (∼7 days post-MCAO), the latter study administered cells at an acute (24 h) timepoint.